In addition, studies have found that patients with CHD4 deletion are sensitive to chemotherapy, but the deletion of CHD4 in BRCA2 mutant cells can enhance the resistance of cancer cells to cisplatin and PARP inhibitors by opening a channel known as “DNA damage tolerance” [37]. The gene discussed is BRCA2; the disease is cancer.